Heron Therapeutics (HRTX)
(Delayed Data from NSDQ)
$1.81 USD
+0.06 (3.43%)
Updated Aug 5, 2025 04:00 PM ET
After-Market: $1.80 -0.01 (-0.55%) 4:52 PM ET
3-Hold of 5 3
C Value F Growth C Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
HRTX 1.81 +0.06(3.43%)
Will HRTX be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for HRTX based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for HRTX
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
HRTX: What are Zacks experts saying now?
Zacks Private Portfolio Services
Compared to Estimates, Heron Therapeutics (HRTX) Q1 Earnings: A Look at Key Metrics
Heron Therapeutics (HRTX) Q1 Earnings and Revenues Top Estimates
MTD Q1 Earnings Top Estimates, Sales Decline Y/Y, Shares Rise
Other News for HRTX
Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025 | ...
Heron Therapeutics: Middling Performance From Approved Therapies With No Pipeline
JW Asset Management, LLC Adjusts Position in Establishment Labs Holdings Inc
Heron Therapeutics Holds Annual Stockholders Meeting
Edison, Apple, Oklo, Heron, Fifth Third: Trending by Analysts